TUCSON, AZ / ACCESS Newswire / November 13, 2025 / Umbrella Labs today announced the research-only availability of three widely studied compounds-Retatrutide (LY-3437943), MK-677 (Ibutamoren), and RAD-140 (Testolone)-as part of a broader 2025 upgrade to its investigational catalog, documentation, and quality-assurance workflows. The rollout places Retatrutide first in line, followed by MK-677 and RAD-140, and introduces unified research briefs that consolidate peer-reviewed context, assay notes, and lot-level analytics to help laboratories plan sample handling, method development, control selection, and analytical endpoints with greater reproducibility. The new program also standardizes labeling, stability guidance, and QR-linked Certificates of Analysis (COAs) to support in-house verification, material tracking, and GLP-aligned recordkeeping in academic and private research settings.

"Investigators are asking for three things at once-clarity on what the literature actually reports, transparency about how lots are verified, and practical details to reproduce measurements in-house," said Samuel Yanner, Director of Scientific Operations at Umbrella Labs. "By shipping each release with a research brief, expanded COA data, and explicit notes on sample handling and solvent compatibility, we're making it simpler to scope experiments responsibly and compare results across time, labs, and lots."

Why this release matters to investigators

Research programs that evaluate energy balance, endocrine signaling, muscle and bone biology, and related mechanistic pathways often rely on a tight chain between material identity, purity, solvent behavior, storage conditions, and analytical method transfer. Variability at any point-source documentation, labeling, or stability-can weaken conclusions or inflate repeat costs. Umbrella Labs' 2025 standard aligns product labeling, batch-level documentation, and reference-method notes across three high-interest compounds so that labs can plan controls, spike-recoveries, and stability checks with a consistent baseline. Each listing includes a research brief summarizing relevant preclinical and clinical literature contexts (as applicable), analytical considerations for identity and purity verification, and practical points such as light sensitivity, agitation guidance for suspensions, and recommended storage ranges. For labs managing multi-site or multi-year studies, the new format also improves auditability via QR-linked batch pages that consolidate the COA, impurity overview, and lot identifiers.

Retatrutide (LY-3437943) - Investigational peptide vial (research-only)

Retatrutide heads today's announcement as a prioritized addition for metabolic and endocrine research domains. The research brief outlines mechanistic rationales around multi-receptor incretin biology and provides a scaffold to help labs plan cohort design, reference standards, and downstream bioanalytical endpoints. Umbrella Labs supplies Retatrutide in a research-grade vial with lot-specific identity and purity verification, accompanied by expanded documentation that clarifies storage guidance and handling considerations relevant to stability and assay reproducibility. The listing includes solvent compatibility notes for typical lab workflows, method-transfer tips to align with HPLC and LC-MS/MS identity checks, and traceability via a QR-coded COA page that consolidates batch data and impurity summaries.

Product page:

Retatrutide (LY-3437943) peptide vial (research-only): https://umbrellalabs.is/shop/peptides/peptide-vials/retatrutide-ly-3437943/

MK-677 (Ibutamoren) - Investigational 25 mg/mL liquid suspension (research-only)

MK-677 is provided as a 25 mg/mL laboratory suspension engineered for consistent resuspension and sampling, with clear agitation guidance and light-exposure notes on the listing to reduce handling-related variability. The research brief summarizes controlled human and preclinical literature contexts around ghrelin-receptor agonism, pulsatile GH/IGF-1 signaling, and secondary exploratory endpoints such as sleep architecture and body-composition proxies, always framed for non-clinical research interpretation. Labs get explicit documentation on physical behavior under storage and routine handling, recommended accuracy checks, and method-transfer pathways for identity/purity verification. The updated 2025 format enhances optical inspection notes and sampling considerations to support repeatable aliquoting in longitudinal work.

Product page:

MK-677 (Ibutamoren) investigational liquid suspension: https://umbrellalabs.is/shop/sarms/sarm-liquid/mk-677-ibutamoren-nutrobal/

RAD-140 (Testolone) - Investigational 20 mg/mL SARM solution (research-only)

RAD-140 is supplied as a 20 mg/mL solution with optical-clarity benchmarks disclosed on the COA and an impurity-profiling overview to aid risk assessment and cross-method verification. The research brief recaps the discovery literature on selective androgen receptor modulation and emphasizes contexts where skeletal muscle and bone endpoints have been studied in preclinical systems, while also noting in vitro and neuronal model signals reported in the literature. The 2025 standard details storage, solvent compatibility, and label transparency so labs can plan stability checks and replicate measurements across timepoints with greater confidence. As with all listings in this release, a QR-linked COA consolidates batch identity, potency results, and impurity summaries.

Product page:

RAD-140 (Testolone) investigational SARM liquid: https://umbrellalabs.is/shop/sarms/sarm-liquid/rad-140-sarm-testolone/

What's new in Umbrella Labs' 2025 documentation standard

This release debuts a harmonized research-brief format across the catalog to help teams translate the literature into scoping and method steps. Each brief is structured to address three common pain points: 1) what the literature actually reports and where gaps remain; 2) how lots are verified before shipment, including which analytical methods support identity and potency; and 3) which practical handling details influence stability, sampling accuracy, and method transfer. The 2025 standard also adds a persistent QR code on every unit that resolves to a batch page with the COA, impurity overview, and lot identifiers for traceability-removing guesswork for internal QA/QC teams and simplifying documentation for audits and manuscript methods sections.

Expanded quality, methods, and data access

Umbrella Labs supplies ISO-accredited third-party testing for identity, purity, and potency, incorporating HPLC, LC-MS/MS, and NMR where applicable. Identity is supported by orthogonal methods to reduce false positives, while potency is reported with disclosure of reference standards and calibration considerations when available. Impurity summaries contextualize residuals relative to method detection limits and acceptance criteria. Each batch page consolidates these data, so labs can cite a single resource when documenting materials in protocols, preregistrations, or peer-review submissions. For studies that require deeper transparency, Umbrella Labs can coordinate additional method details-such as gradient programs or reference-standard sources-upon request, subject to non-clinical research use and documentation availability.

Handling guidance and stability notes

Because small differences in storage and preparation can influence result quality, each product page includes plain-language handling notes. For Retatrutide vials, the listing clarifies storage ranges and handling considerations relevant to peptide stability and assay reproducibility. For MK-677 suspensions, the listing specifies agitation guidance for consistent sampling and notes on light exposure. For RAD-140 solutions, the listing documents storage and solvent compatibility expectations and recommends simple visual checks for optical clarity. Across all three, units ship in protective secondary packaging with labeling designed to remain legible during cold-chain or room-temperature transit windows defined on the COA. These details allow labs to plan incoming-sample checklists and record handling steps in ELNs for reproducibility.

Catalog access and product links

Investigators can access the product listings directly and review lot-level documentation and research briefs prior to ordering:

Retatrutide (LY-3437943): https://umbrellalabs.is/shop/peptides/peptide-vials/retatrutide-ly-3437943/
MK-677 (Ibutamoren) investigational liquid: https://umbrellalabs.is/shop/sarms/sarm-liquid/mk-677-ibutamoren-nutrobal/
RAD-140 (Testolone) investigational SARM liquid: https://umbrellalabs.is/shop/sarms/sarm-liquid/rad-140-sarm-testolone/

Ethics, compliance, and intended use

All materials in this announcement are intended strictly for laboratory research. They are not approved for human use, clinical administration, diagnostic procedures, or dietary supplementation. Umbrella Labs supports anti-doping policies and does not condone use in sport; listings carry research-only labeling, usage restrictions, and batch-level documentation to support responsible, non-clinical work. Customers acknowledge and agree that procurement, storage, and use are limited to qualified research personnel operating within applicable institutional and legal frameworks.

Customer experience upgrades for 2025

The new documentation standard is matched by operational updates that target speed, clarity, and traceability. A redesigned batch-lookup flow enables scanning the on-unit QR code to retrieve the COA, impurity overview, and lot IDs within seconds. Purchase confirmations link directly to the relevant batch page so labs can attach documents to ELNs or LIMS records without manual searching. Label formats now include unambiguous product names, concentrations (for liquids), and storage indicators to reduce intake errors. For multi-site projects, unit labels and batch pages share the same identifiers so that cross-location teams can coordinate via a single source of truth.

Support for method transfer and in-house verification

Umbrella Labs recognizes that many laboratories prefer to verify identity and potency upon receipt. To that end, each product page offers method-transfer notes that outline practical steps for common analytical approaches, including considerations for sample prep, solvent systems, and expected retention or mass-spec behaviors under typical conditions. While exact parameters vary by instrument and column chemistry, these notes shorten the time from receipt to verified readiness, helping labs focus resources on experimental design rather than materials troubleshooting. Where appropriate, Umbrella Labs can, upon request, provide additional reference information to support internal validation processes for non-clinical research.

What investigators can expect next

As the 2025 catalog expands, Umbrella Labs will continue to publish research briefs that emphasize clarity and reproducibility. Upcoming releases will apply the same documentation standard, aligning batch transparency with literature-anchored context and practical guidance for handling, storage, and method transfer. The goal is to build a consistent, lab-friendly framework where every unit ships with data that matter to experimental outcomes-identity, purity, potency, impurity context, and the concrete handling details that help ensure comparable results over time.

A second statement from operations

"Our commitment is to make the responsible path the easy path," added Yanner. "When the labeling is clear, the COA is one scan away, and the research brief spells out what's known and what's not, labs can design smarter experiments and defend their methods. It helps reviewers, it helps future readers, and it helps the investigators doing the work today."

How to order and inquire

Investigators can review the research briefs and batch documentation at the product links listed above, then proceed to order through standard procurement accounts. For bulk requests, institution-specific documentation packages, or questions about reference-standard sourcing, teams may contact Umbrella Labs using the details below. Umbrella Labs maintains supply-chain controls and retains batch samples for post-market analytical inquiries, reinforcing traceability throughout a lot's lifecycle.

Location, contact, and institutional access

Umbrella Labs
3280 E Hemisphere Loop
Tucson, AZ 85706
support@umbrella-labs.us
1-866-289-7276

About Umbrella Labs

Umbrella Labs is a U.S.-based supplier of research-grade peptides, SARMs, and biochemical reagents. Known for its purity-verification systems, stringent supply-chain controls, and dedication to data transparency, the company serves academic and private research clients across North America, Europe, and Asia. Each unit ships with QR-linked documentation designed to support audit-ready recordkeeping and reproducible, non-clinical laboratory research. For more information on current inventory, documentation standards, and research-only access, visit the product pages directly:

Media inquiries

Press and institutional communications: support@umbrella-labs.us
Phone: 1-866-289-7276

Ethics reminder
All materials are for laboratory research only. Not for human use, clinical administration, or dietary supplementation. Umbrella Labs supports anti-doping policies and marks listings with research-only labeling and restrictions to reinforce responsible use within appropriate institutional frameworks.

SOURCE: Umbrella Labs